Non-exclusive discount agreement for medicines containing brinzolamide and brimonidine

Summary

The tender concerns a framework agreement for medicines containing the active substance brinzolamide + brimonidine (ATC S01EC24). DAK-Gesundheit intends to conclude discount agreements with as many interested pharmaceutical companies as possible for the period from 1 September 2026 to 31 August 2028, with an option to extend the contract once for 12 months. The bidder should note that the exact qualification and compliance requirements must be checked in the tender documents.